| 前收盘价格 | 177.56 |
| 成交量 | 4,246,940 |
| 预期市盈率 (P/E Forward) | 19.49 |
| 价格/销量 (P/S) | 3.82 |
| 股市价格/股市净资产 (P/B) | 4.04 |
| 52周波幅 | |
| 股息率 (DY TTM) | 2.44% |
| 营业毛利率 | 18.04% |
| 营业利益率 (TTM) | 32.68% |
| 稀释每股收益 (EPS TTM) | 8.34 |
| 季度收入增长率 (YOY) | 5.30% |
| 季度盈利增长率 (YOY) | 5.60% |
| 总债务/股东权益 (D/E MRQ) | 58.23% |
| 流动比率 (MRQ) | 1.86 |
| 营业现金流 (OCF TTM) | 2.95 B |
| 杠杆自由现金流 (LFCF TTM) | 1.78 B |
| 资产报酬率 (ROA TTM) | 6.69% |
| 股东权益报酬率 (ROE TTM) | 14.35% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (AU) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | CSL FPO [CSL] | - | - |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 4.0 |
| 平均 | -0.06 |
|
CSL is one of the largest global biotech companies and has three main segments. CSL Behring uses either plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D record, and its product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and one-fourth in Europe. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Core |
| 内部持股比例 | 0.30% |
| 机构持股比例 | 35.79% |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合